Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $84.61M | $73.48M | $65.05M | $85.49M | $78.65M | $65.21M | $37.77M | $9.39M |
| Cost of Revenue | $57.79M | $55.27M | $51.70M | $53.84M | $58.53M | $43.13M | $25.97M | $11.74M |
| Gross Profit | $26.82M | $18.21M | $13.35M | $31.66M | $20.11M | $22.08M | $11.80M | $-2.34M |
| Gross Margin | 31.70% | 24.78% | 20.52% | 37.03% | 25.57% | 33.86% | 31.25% | -24.94% |
| Operating Expenses | $95.09M | $128.14M | $128.88M | $97.01M | $62.26M | $44.50M | $25.57M | $19.82M |
| Operating Income | $-68.27M | $-109.94M | $-115.53M | $-65.35M | $-42.15M | $-22.42M | $-13.77M | $-22.16M |
| Operating Margin | -80.68% | -149.61% | -177.61% | -76.44% | -53.59% | -34.38% | -36.45% | -235.95% |
| Net Income | $-81.28M | $-108.30M | $-113.31M | $-65.23M | $-41.28M | $-25.08M | $-19.89M | $-23.60M |
| Net Margin | -96.06% | -147.38% | -174.20% | -76.29% | -52.49% | -38.47% | -52.64% | -251.23% |
| EPS (Basic) | $-1.37 | $-2.25 | $-2.48 | $-1.49 | $-1.20 | $-1.39 | $-0.91 | $-1.08 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |